Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.56 Insider Own2.27% Shs Outstand145.08M Perf Week5.93%
Market Cap596.28M Forward P/E- EPS next Y-1.08 Insider Trans-0.01% Shs Float141.79M Perf Month4.05%
Income-225.25M PEG- EPS next Q-0.35 Inst Own95.41% Short Float6.48% Perf Quarter-5.95%
Sales170.28M P/S3.50 EPS this Y15.91% Inst Trans-3.10% Short Ratio6.45 Perf Half Y-38.47%
Book/sh2.12 P/B1.93 EPS next Y17.73% ROA-29.68% Short Interest9.19M Perf Year-51.93%
Cash/sh2.39 P/C1.72 EPS next 5Y21.60% ROE-58.32% 52W Range2.61 - 9.17 Perf YTD-16.12%
Dividend Est.- P/FCF- EPS past 5Y-32.91% ROI-56.64% 52W High-55.18% Beta1.27
Dividend TTM- Quick Ratio4.50 Sales past 5Y33.92% Gross Margin45.49% 52W Low57.77% ATR (14)0.28
Dividend Ex-Date- Current Ratio4.66 EPS Y/Y TTM-10.98% Oper. Margin-118.40% RSI (14)52.63 Volatility6.13% 6.89%
Employees790 Debt/Eq0.32 Sales Y/Y TTM-8.11% Profit Margin-132.29% Recom1.50 Target Price6.83
Option/ShortYes / Yes LT Debt/Eq0.29 EPS Q/Q-70.84% Payout- Rel Volume0.73 Prev Close4.15
Sales Surprise-5.51% EPS Surprise-44.88% Sales Q/Q-17.05% EarningsFeb 14 AMC Avg Volume1.43M Price4.11
SMA207.07% SMA50-3.69% SMA200-26.05% Trades Volume1,035,657 Change-0.96%
Date Action Analyst Rating Change Price Target Change
Jul-05-23Resumed JP Morgan Overweight $15
Jan-05-23Initiated Scotiabank Sector Outperform $15
Dec-21-22Upgrade Piper Sandler Neutral → Overweight $7.50 → $14
Aug-25-22Initiated Credit Suisse Underperform $8
Jun-03-22Initiated Piper Sandler Neutral $7.50
Feb-16-22Reiterated JP Morgan Overweight $75 → $50
Feb-16-22Reiterated Goldman Neutral $54 → $21
Feb-16-22Reiterated BTIG Research Buy $35 → $30
Feb-16-22Reiterated BofA Securities Buy $40 → $32
Oct-15-21Resumed Cowen Outperform
Feb-22-24 04:05PM
Feb-15-24 10:09AM
Feb-14-24 05:16PM
04:05PM Loading…
Feb-13-24 02:23AM
Feb-12-24 09:16AM
Jan-29-24 04:05PM
Dec-27-23 04:05PM
Dec-12-23 05:50AM
Dec-11-23 03:30PM
Dec-09-23 08:30AM
Dec-05-23 07:30AM
Nov-10-23 01:52PM
04:17PM Loading…
Nov-09-23 04:17PM
Nov-07-23 07:30AM
Nov-02-23 04:05PM
Oct-26-23 10:02AM
Oct-17-23 07:57AM
Sep-27-23 05:14AM
Sep-13-23 07:30AM
Aug-30-23 04:30PM
Aug-28-23 11:53PM
Aug-24-23 10:29AM
Aug-02-23 05:35PM
Jul-29-23 12:12AM
08:52AM Loading…
Jul-19-23 08:52AM
Jul-10-23 04:05PM
Jun-24-23 03:19PM
Jun-16-23 05:02PM
Jun-02-23 10:15AM
May-29-23 08:08AM
May-26-23 09:45AM
May-24-23 04:05PM
May-23-23 09:54AM
May-15-23 07:50AM
May-12-23 08:00AM
May-09-23 07:30AM
May-04-23 09:13AM
May-03-23 05:25PM
Apr-27-23 10:02AM
Apr-26-23 10:02AM
Apr-25-23 04:05PM
Apr-24-23 09:40AM
Apr-18-23 12:10PM
Apr-12-23 07:30AM
Apr-06-23 04:05PM
Mar-29-23 04:20PM
Mar-27-23 09:40AM
Mar-16-23 11:41AM
Mar-10-23 10:42AM
Mar-09-23 09:55AM
Feb-28-23 11:11AM
Feb-27-23 04:05PM
Feb-24-23 11:52AM
Feb-21-23 09:55AM
Feb-14-23 05:55PM
Jan-30-23 07:21AM
Jan-23-23 04:05PM
Jan-10-23 09:00AM
Dec-27-22 04:05PM
Dec-20-22 06:14AM
Dec-10-22 10:00AM
Dec-05-22 07:30AM
Dec-01-22 07:30AM
Nov-21-22 04:05PM
Nov-03-22 06:35PM
Oct-11-22 08:05AM
Oct-05-22 04:05PM
Sep-15-22 06:48AM
Sep-14-22 05:22PM
Sep-12-22 08:30AM
Sep-02-22 08:00AM
Aug-14-22 11:13AM
Aug-04-22 12:00AM
Aug-03-22 05:35PM
Aug-02-22 10:07AM
Jul-28-22 10:02AM
Jul-27-22 10:01AM
Jul-18-22 06:56AM
Jul-08-22 04:05PM
Jun-16-22 12:49PM
Jun-15-22 07:30AM
Jun-10-22 05:00PM
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NEUPERT PETER MDirectorDec 13Option Exercise0.84100,00084,000122,968Dec 15 04:21 PM
PISKEL KYLEPrincipal Accounting OfficerNov 16Sale4.132591,07087,305Nov 20 05:30 PM
SOOD NITINChief Commercial Officer, MRDAug 08Sale6.5410,55068,997214,808Aug 08 04:53 PM
SOOD NITINChief Commercial Officer, MRDAug 07Sale6.785,65238,321225,358Aug 08 04:53 PM
PETERSON TYCHOChief Financial OfficerJun 20Option Exercise7.30134,961985,215534,180Jun 21 05:32 PM
PETERSON TYCHOChief Financial OfficerJun 20Sale8.14134,9611,098,583399,219Jun 21 05:32 PM
PETERSON TYCHOChief Financial OfficerJun 15Option Exercise7.3014,328104,594413,547Jun 20 05:41 PM
PETERSON TYCHOChief Financial OfficerJun 15Sale8.5370,000597,100399,219Jun 20 05:41 PM
PETERSON TYCHOChief Financial OfficerJun 02Sale7.1638,000272,080454,891Jun 06 04:23 PM
ADAMS R MARKChief Operating OfficerApr 11Sale8.632,30819,918175,361Apr 12 06:04 PM
ADAMS R MARKChief Operating OfficerApr 10Sale8.508176,944177,669Apr 12 06:04 PM
GRIFFIN MICHELLE RENEEDirectorMar 27Sale8.492,34119,87820,627Mar 29 05:01 PM
ADAMS R MARKChief Operating OfficerMar 07Sale8.6017,155147,533178,486Mar 08 08:03 PM
Taylor Stacy LSVP and General CounselMar 07Sale8.6013,387115,128139,678Mar 08 08:04 PM
SOOD NITINChief Commercial Officer, MRDMar 07Sale8.609,81384,392231,010Mar 08 08:01 PM
RUBINSTEIN JULIEPresidentMar 06Sale8.5722,668194,265336,824Mar 08 08:01 PM
BENZENO SHARONChief Commercial Ofc Imm MedMar 06Sale8.5711,749100,689223,826Mar 08 08:02 PM
LO FRANCISChief People OfficerMar 06Sale8.576,81658,413168,469Mar 08 08:04 PM
SOOD NITINChief Commercial Officer, MRDMar 06Sale8.576,66157,085240,823Mar 08 08:01 PM
ADAMS R MARKChief Operating OfficerMar 06Sale8.576,52955,954195,641Mar 08 08:03 PM
Taylor Stacy LSVP and General CounselMar 06Sale8.575,49147,058153,065Mar 08 08:04 PM
PISKEL KYLEPrincipal Accounting OfficerMar 06Sale8.573,52930,24687,564Mar 08 08:04 PM